Jnana Therapeutics Inc. has synthesized sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of amino acid metabolism disorders, amino ...

The data demonstrate that SLC6A19 inhibition results in a dose-dependent increase in urinary excretion of amino acids, including phenylalanine (Phe), and lowers plasma Phe levels in a PKU mouse model.

The SLC transporter SLC6A19 is responsible for kidney reabsorption of Phe back into the bloodstream, and the inhibition of SLC6A19 offers a novel approach for the treatment of PKU.